Clinical trials: Peritoneal Dialysis, Heart Failure
End Stage Renal Disease
Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients
Individuals with kidney disease are at a higher risk for heart and vascular diseases, including heart attacks and strokes, than those with normal kidney function.
- Trial name
- NCT01427374
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Peritoneal Dialysis Complication, Hemodialysis Complication
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
Patients with end stage renal disease (ESRD), especially after having maintenance dialysis are among the highest risk of heart failure (HF), which is the most important cause that affects survival rate and quality of life.
- Conditions
- Peritoneal Dialysis Complication, Hemodialysis Complication, Heart Failure
- Trial name
- NCT04572724
- Testing
- Sacubitril / Valsartan Oral Tablet, RAS Inhibitors
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Second People's Hospital
Kidney Disease, Peritoneal Dialysis (PD)
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.
- Conditions
- Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
- Trial name
- SCALE-PD (NCT07059962)
- Testing
- Bodyport Cardiac Scale
- Where
- 7 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- Bodyport Inc.
ESRD, CKD Stage 4, CKD Stage 5
Canagliflozin in Advanced Renal Disease With MRI Endpoints
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance…
- Trial name
- CARe-MRI (NCT06182839)
- Testing
- Canagliflozin 300Mg Tab
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Refractory Heart Failure, Chronic Kidney Disease
The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease
In patients with advanced heart failure (HF), systemic congestion is the main indication for hospitalization. Recent evidence has highlighted the role of fluid retention in the pathogenesis of renal dysfunction and subsequent…
- Trial name
- NCT01758627
- Testing
- Peritoneal dialysis (PD)
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Yonsei University
Heart Failure, Cardio-Renal Syndrome
A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure
A single-center, prospective, non-randomized, clinical and first-in-human study. Each patient will be studied during a single treatment session of ten hours.
- Trial name
- NCT02772146
- Testing
- CLS UF
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Triomed AB
Cardiovascular Diseases, Inflammation
Evaluation of Volume Status in Peritoneal Dialysis Patients
Patients with kidney failure on dialysis have a much higher risk of developing cardiovascular disease as compared to the general population.
- Conditions
- Cardiovascular Diseases, Inflammation, Peritoneal Dialysis
- Trial name
- NCT00182338
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McMaster University
Heart Failure, Chronic Kidney Disease
PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease
This trial is to establish whether ultrafiltration by peritoneal dialysis is a clinically effective treatment for patients with severe heart failure and moderate chronic kidney disease, thus improving quality of life and symptoms.
- Trial name
- PD-HF (NCT02708407)
- Testing
- Peritoneal Dialysis
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- University of Nottingham
End-Stage Renal Disease
Vitamin D3 Supplementation in Dialysis Patients
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide.
- Trial name
- NCT01312714
- Testing
- Cholecalciferol
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Regional Hospital Holstebro
End-Stage Renal Disease, Osteoporosis
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) patients have not been…
- Trial name
- NCT00261625
- Testing
- alendronate
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Congestive Heart Failure
Peritoneal Dialysis in Congestive Heart Failure
Rationale: End-stage congestive heart failure is a serious invalidating condition with a poor prognosis and increasing incidence.
- Trial name
- PDinCHF (NCT01124227)
- Testing
- icodextrin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Martini Hospital Groningen
Peritoneal Dialysis, Cardiovascular Diseases
The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients
This study aims to explore how daily physical activity (PA) levels affect the heart health and cognitive function of patients on peritoneal dialysis (PD).
- Conditions
- Peritoneal Dialysis, Cardiovascular Diseases, Myocardial Infarct, Heart Failure
- Trial name
- NCT06697418
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Ruijin Hospital
Cardiovascular Diseases, Carotid Intimal Media Thickness
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis.
- Conditions
- Cardiovascular Diseases, Carotid Intimal Media Thickness, Left Ventricular Hypertrophy, Mean Platelet Volume
- Trial name
- NCT03759002
- Testing
- Imaging, Blood sampling
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Heart Failure, End Stage Renal Disease
Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients
Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis.
- Trial name
- SONGBIRD (NCT04061811)
- Testing
- Diagnostic biomarker study
- Where
- 2 sites in France, Germany
- Volunteers
- 153 people
- Sponsor
- Hannover Medical School
Potential Applications for Heart Failure, Volume Overload
Zero Sodium Peritoneal Dialysate Protocol Pilot Study
The following pilot study will be undertaken to determine the effects of use of a zero-sodium peritoneal dialysate solution (10% dextrose in sterile water) on sodium removal as compared to a standard peritoneal dialysis solution.
- Trial name
- NCT03801226
- Testing
- Two-hour dwell with 10% dextrose in sterile water, Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Peritoneal Lesion
NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants
Urinary NGAL has been shown to be an early marker of acute kidney injury (AKI) following paediatric cardiac surgery (2 hours off pump).
- Trial name
- NGAL (NCT01219998)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peritoneal Dialysis, Heart Failure
Exploring Water-free Sodium Storage
The overarching goal of this proposal is to definitively establish if acute water free Na storage and release occurs, if the amount stored/released is of a quantity that is physiologically relevant, and if the location is…
- Trial name
- NOS (NCT06872645)
- Testing
- 5% Dextrose/Water, 1.5% standard PD fluid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Heart Failure
Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients
Background Heart failure is the final consequence of various heart disease and is also the leading cause of mortality worldwide.
- Trial name
- ALEVENT (NCT01503671)
- Testing
- Atorvastatin
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- National Taiwan University Hospital
Cardio-renal Syndrome
Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome
Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure.
- Trial name
- UF-CARE (NCT02846337)
- Testing
- ULTRAFILTRATION, ENHANCED MEDICAL TREATMENT
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
Disorders Associated With Peritoneal Dialysis
Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study)
The main purpose of this study is to compare the effects of using bio-impedance analysis to guide management of fluid status versus routine clinical care on heart structure.
- Trial name
- FLUID (NCT01045980)
- Testing
- Bioimpedance and Vitamin D, Usual care and Vitamin D
- Where
- 2 sites in Canada
- Volunteers
- 74 people
- Sponsor
- St. Joseph's Healthcare Hamilton